Prospective Randomized Endovascular Therapy in Multiple Sclerosis - PREMiSE

Inclusion Criteria

• •Age 18-65 years
• •EDSS 0-6.5 (0-5.5 in the phase II of the study)
• •Diagnosis of relapsing MS according to the McDonald criteria (Polman et al., 2005)
• •1 relapse within the past 12 months or GAD positive lesion on an MRI within the past 3 months (only for phase II of the study)
• •Be on treatment with currently FDA approved disease-modifying treatments (excluding Tysabri or steroids (within the last 30 days prior to enrollment)
• •Evidence of ≥2 sonographic parameters of suspicious abnormal extracranial cerebral venous outflow (see Table 1 background and 1.5 section)
• •Normal renal function: creatinine clearance level of \>60